Healthcare Industry News: PENTAX Medical
News Release - November 2, 2016
HOYA Group PENTAX Medical Launch HemoStat WideCup(TM), The New Bipolar Hot Hemostasis Forceps Contributing to Early Treatment of Gastric CancerTOKYO, Nov. 2, 2016 -- (Healthcare Sales & Marketing Network) -- HOYA Group PENTAX Medical has launched HemoStat WideCupTM, the new bipolar hot hemostasis forceps to achieve easy control of bleeding during endoscopic therapy procedures. The new device will be demonstrated at the JDDW 2016 Congress to be held in Kobe, Japan from November 3rd through 6th, 2016.
"PENTAX Medical is commited to strengthening our endoscopic therapy portfolio to support better patient care. The HemoStat WideCupTM is a highly innovative hemostasis device designed to greatly simplify the control of bleeding," said Gerald W. Bottero, Global President, PENTAX Medical. 'We are confident the HemoStat WideCupTM sets a new standard for precise, efficient and safer endoscopic therapy, and will further support global growth of early screening and treatment of gastric cancer. We are commited to propagate and further develop this procedure."
HemoStat WideCupTM's benefit and features include:
Easy Control of Bleeding by
- Wide cup – for easy grasp of bleeding point (Opening width - existing version: 4.0mm, HemoStat WideCupTM: 5.8mm)
- Less handling power – for easy operation (30-40% reduction of handling power than existing version)
PENTAX Medical is a division of HOYA Group. Its mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. Through leading edge R&D and manufacturing, PENTAX Medical provides endoscopic imaging devices and solutions to the global medical community. Headquartered in Japan, PENTAX Medical has a worldwide focus and presence with R&D, regional sales, service, and in-country facilities around the globe. For more information, please visit: www.pentaxmedical.com.
Source: PENTAX Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.